Dynamics of bubble rising at small Reynolds numbers

Results of experimental study of a single spherical bubble rising in the non-stationary regime in a viscous liquid (with and without surfactant) at small Reynolds numbers Re<1 have been presented. Improved empirical correlations for drag coefficient of the bubble rising with and without surfactant in the stationary regime have been obtained. Influence of nonstationary effects on the dynamics of bubble rising has been analyzed

Information Technology and Pragmatic Analysis

Similarity method has been in science for several centuries. The basis of the study is closely connected with mathematical linguistics. This approach has allowed obtaining new results in the analytical geometry, which, in turn, is used in different applications in information technology. The results are described briefly. Binary relations in linguistics and geometry are compared with the position of system analysis. The modified hypothesis of space as a binary structure is put forward on the basis of singular linear transformations. The hypothesis of the human sensory system is given shortly. Architecture computing appliance for solving this class of problems is proposed. The modified method is also applied in pattern recognition. The presence of symmetry in natural languages is shown briefly

Unsteady rise of a bubble in a viscous fluid at small Reynolds numbers

A bubble rising from the state of rest in a viscous incompressible fluid is considered. A formula for the Basset force acting on the bubble in a viscous fluid is obtained, which differs by a multiplier from the Basset force for a solid particle. The problem of unsteady rise of a bubble is solved analytically. The bubble rise is also studied experimentally and the experimental data are compared with the theoretical results

Stopping of charged particles in dense one-component plasmas

Arkhipov, YV.; Askaruly, A.; Ashikbayeva, A.; Dubovtsev, D.; Syzganbayeva, S.; Tkachenko Gorski, IM. (2018). Stopping of charged particles in dense one-component plasmas. Recent Contribution to Physics. 65(2):51-57. http://hdl.handle.net/10251/133780S515765

Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms

Observational studies indicate that overutilization of inhaled corticosteroids (ICS) is common in patients with chronic obstructive pulmonary disease (COPD). Overprescription and the high risk of seriou

Analysis of methods for calculating the static characteristics of dense Coulomb systems

[EN] In this paper, various methods for calculating static characteristics of plasma, such as HNC, MHNC, VMHNC, Percus-Yevik and analytical models were analyzed to satisfy a mathematical condition. Structural characteristics of a one-component plasma were reconstructed in a wide range of coupling parameters within the most requested various modern methods (HNC, MHNC, VMHNC, Percus-Yevik, and analytical models). All these methods were analyzed to fulfill the fundamental Cauchy ¿ Schwartz mathematical inequality. As a result a HNC method with the empirical expression of the bridge function and one of the recent methods for obtaining a structural factor based on a parameterized formula does not satisfy the inequality. The other methods for calculating static characteristics listed above beside the stated ones satisfy the condition. For the general analysis of a method, functional dependence was obtained expressing the Cauchy-Schwartz inequality. This dependence includes the frequency moments, which are defined within the framework of the method of moments. To satisfy the inequality, this relationship must be strictly positive. For each considered method of obtaining static structural characteristics, this relationship was calculated and analyzed. As a result, it was found that a number of methods do not satisfy the Cauchy-Schwartz inequality.Arkhipov, YV.; Askaruly, A.; Ashikbayeva, A.; Davletov, A.; Dubovtsev, D.; Santybayev, K.; Tkachenko Gorski, IM. (2018). Analysis of methods for calculating the static characteristics of dense Coulomb systems. Recent Contribution to Physics. 67(4):20-32. http://hdl.handle.net/10251/133778S203267

Russian guidelines for the management of COPD: algorithm of pharmacologic treatment

The high prevalence of COPD together with its high level of misdiagnosis and late diagnosis dictate the necessity for the development and implementation of clinical practice guidelines (CPGs) in order to improve the management of this disease. High-quality, evidencebased international CPGs need to be adapted to the particular situation of each country or region. A new version of the Russian Respiratory Society guidelines released at the end of 2016 was based on the proposal by Global Initiative for Obstructive Lung Disease but adapted to the characteristics of the Russian health system and included an algorithm of pharmacologic treatment of COPD. The proposed algorithm had to comply with the requirements of the Russian Ministry of Health to be included into the unified electronic rubricator, which required a balance between the level of information and the simplicity of the graphic design. This was achieved by: exclusion of the initial diagnostic process, grouping together the common pharmacologic and nonpharmacologic measures for all patients, and the decision not to use the letters A–D for simplicity and clarity. At all stages of the treatment algorithm, efficacy and safety have to be carefully assessed. Escalation and de-escalation is possible in the case of lack of or insufficient efficacy or safety issues. Bronchodilators should not be discontinued except in the case of significant side effects. At the same time, inhaled corticosteroid (ICS) withdrawal is not represented in the algorithm, because it was agreed that there is insufficient evidence to establish clear criteria for ICSs discontinuation. Finally, based on the Global Initiative for Obstructive Lung Disease statement, the proposed algorithm reflects and summarizes different approaches to the pharmacological treatment of COPD taking into account the reality of health care in the Russian Federation

Genotyping of Capreolus pygargus Fossil DNA from Denisova Cave Reveals Phylogenetic Relationships between Ancient and Modern Populations

BACKGROUND: The extant roe deer (Capreolus Gray, 1821) includes two species: the European roe deer (C. capreolus) and the Siberian roe deer (C. pygargus) that are distinguished by morphological and karyotypical differences. The Siberian roe deer occupies a vast area of Asia and is considerably less studied than the European roe deer. Modern systematics of the Siberian roe deer remain controversial with 4 morphological subspecies. Roe deer fossilized bones are quite abundant in Denisova cave (Altai Mountains, South Siberia), where dozens of both extant and extinct mammalian species from modern Holocene to Middle Pleistocene have been retrieved. METHODOLOGY/PRINCIPAL FINDINGS: We analyzed a 629 bp fragment of the mitochondrial control region from ancient bones of 10 Holocene and four Pleistocene Siberian roe deer from Denisova cave as well as 37 modern specimen belonging to populations from Altai, Tian Shan (Kyrgyzstan), Yakutia, Novosibirsk region and the Russian Far East. Genealogical reconstructions indicated that most Holocene haplotypes were probably ancestral for modern roe deer populations of Western Siberia and Tian Shan. One of the Pleistocene haplotypes was possibly ancestral for modern Yakutian populations, and two extinct Pleistocene haplotypes were close to modern roe deer from Tian Shan and Yakutia. Most modern geographical populations (except for West Siberian Plains) are heterogeneous and there is some tentative evidence for structure. However, we did not find any distinct phylogenetic signal characterizing particular subspecies in either modern or ancient samples. CONCLUSION/SIGNIFICANCE: Analysis of mitochondrial DNA from both ancient and modern samples of Siberian roe deer shed new light on understanding the evolutionary history of roe deer. Our data indicate that during the last 50,000 years multiple replacements of populations of the Siberian roe deer took place in the Altai Mountains correlating with climatic changes. The Siberian roe deer represent a complex and heterogeneous species with high migration rates and without evident subspecies structure. Low genetic diversity of the West Siberian Plain population indicates a recent bottleneck or founder effect

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049